Baird analyst Eric Coldwell upgraded Iqvia (IQV) to Outperform from Neutral with a price target of $258, up from $224. The firm sees a “moderately improving environment” for the company and likes its longer-term opportunity. There are limited ways investors can directly play a clinical, commercial research and development recovery and Iqvia seems “to be taking more steps forward than backward,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- IQVIA Holdings Reports Strong Q3 2025 Results
- IQVIA Holdings: Strong Earnings and Strategic Growth
- Iqvia sees Q4 adjusted EPS $3.35-$3.45, consensus $3.39
- IQVIA Holdings: Hold Rating Amid Stable Performance and Limited Upside Potential
- Resilient Growth and Strong Segment Performance Drive Buy Rating for IQVIA Holdings